"We Envision Growth Strategies Most Suited
to Your Business"

Orphan Drugs Market Size to Record 11.6% CAGR Over 2023-2030; Rising Number of Patients Suffering from Rare Diseases to Propel Market Growth

July 28, 2023 | Healthcare

The global orphan drugs market size touched USD 156.97 billion in 2022 and is predicted to reach USD 170.49 billion in 2023. The market is anticipated to touch USD 368.43 billion by 2030, recording a CAGR of 11.6% over 2023-2030.


Fortune Business Insights™ presents this information in its latest report titled Orphan Drugs Market Size, Share & COVID-19 Impact Analysis, By Therapy Area (Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy, Infectious Diseases, and Others), By Drug Type (Biologics and Non-Biologics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), and Regional Forecast, 2023-2030”.


Orphan drugs refer to a set of medicines that have been developed by end-users in the pharmaceutical sector to address public health requirements. These medicines can effectively treat patients suffering from rare disorders as these ailments do not have any treatment available. According to an article published by the Orphanet in 2023, nearly 4,000-5,000 rare ailments do not have any treatment. These factors are predicted to boost the orphan drugs market share in the coming years.


Rising Product Approvals Favored Market Growth During COVID-19 Pandemic


While the COVID-19 pandemic had a negative impact on elective surgeries and treatments, such as treatment of rare diseases as most of them were postponed or cancelled, the number of approvals for these drugs rose. The number of applications that were sent by leading pharmaceutical companies to get their orphan drugs approved for commercialization and promotion were higher than that of the pre-pandemic period. This factor improved the market progress during COVID-19.


To get a detailed report summary and research scope of this market, click here:


https://www.fortunebusinessinsights.com/industry-reports/orphan-drugs-market-100088


Rising Number of Patients Suffering from Rare Diseases to Propel Market Growth


The number of patients suffering from rare ailments is increasing at a steady pace across the globe. However, these diseases do not have any treatment, a fact that has prompted many drug-makers to intensify their research and development efforts to create effective therapeutics for rare diseases. Since there is a sizeable percentage of people suffering from these ailments, companies are raising their investments in R&D initiatives and getting involved in the creation of innovative products. These developments are set to drive the orphan drugs market growth during the forecast period.


Competitive Landscape


Vast Product Portfolio of F. Hoffmann-La Roche Ltd. and Bristol-Myers Squibb Company to Help Dominate the Market


The market has a strong presence of organizations that are involved in the production and distribution of a vast range of medicinal products and a vast customer base. However, Bristol-Myers Squibb and F. Hoffman La Roche are dominating this market as these companies have a vast product portfolio and have witnessed strong sales of these drugs that are used to treat several rare cancers. The other companies that have a notable market presence include BioMarin Pharmaceutical Inc., Biogen Inc., Novartis, Alexion, Amgen, DAIICHI SANKYO COMPANY LIMITED, AstraZeneca, and Agios Pharmaceuticals.


Notable Industry Development:



  • April 2022: Kite, a Gilead Company, announced that it received approval from the U.S. FDA for its Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adults diagnosed with large B-cell lymphoma.


List of the Companies Profiled in the Report:



  • Amgen Inc. (U.S.)

  • Bayer AG (Germany)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • Alexion Pharmaceuticals Inc. (U.S.)

  • Novo Nordisk A/S (Denmark)

  • Novartis AG (Switzerland)

  • Bristol-Myers Squibb Company (U.S.)

  • AstraZeneca (U.K.)

  • DAIICHI SANKYO COMPANY, LIMITED (Japan)

  • GlaxoSmithKline plc (U.K.)

  • Other Players


Further Report Findings



  • North America accounted for the largest share of the global market in 2022 due to factors such as high expenditure on the development of orphan drugs, rising patient population, and presence of prominent market players.

  • The market in Asia Pacific is predicted to record the highest growth rate in the global market during the forecast period as the region is increasing its expenditure on healthcare to provide best-in-class treatment for unique ailments. The regional population is also gaining more awareness regarding a wide range of rare diseases, making the APAC region a lucrative market for the development and promotion of orphan drugs.

  • The hospital pharmacy segment is estimated to account for the largest market share during the forecast timeframe as a large percentage of these drugs are administered to patients intravenously by highly trained healthcare professionals. Hence, these pharmacies can make it easier for doctors to gain access to advanced medication.


Table of Segmentation


























































  ATTRIBUTE



  DETAILS



Study Period



2019-2030



Base Year



2022



Estimated Year



2023



Forecast Period



2023-2030



Historical Period



2019-2021



Growth Rate



CAGR of 11.6% from 2023 to 2030



Unit



Value (USD billion)



Segmentation



By Therapy Type, Drug Type, Distribution Channel, and Region



By Therapy Type




  • Oncology

  • Hematology

  • Neurology

  • Endocrinology

  • Cardiovascular

  • Respiratory

  • Immunotherapy

  • Infectious Diseases

  • Others



By Drug Type




  • Biologics

  • Non-biologics



By Distribution Channel




  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

  • Others



By Region




  • North America (By Therapy Type, By Drug Type, By Distribution Channel, By Country)

    • U.S.

    • Canada



  • Europe (By Therapy Type, By Drug Type, By Distribution Channel, By Country/Sub-Region)

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Scandinavia

    • Rest of Europe



  • Asia Pacific (By Therapy Type, By Drug Type, By Distribution Channel, By Country/Sub-Region)

    • Japan

    • China

    • India

    • Australia

    • Southeast Asia

    • Rest of Asia Pacific



  • Rest of the World (By Therapy Type, By Drug Type, By Distribution Channel)


Orphan Drugs Market
  • PDF
  • 2022
  • 2019-2021
  • 135

    CHOOSE LICENSE TYPE

  • 4850
    5850
    6850

Our Clients

Kojler
Ferrero
Caterpillar
3M
BASF
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X